$Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma$

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

<p>Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A) Total CD3+CD8+ cytotoxic T cells...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Julio C. Chavez (15181310) (author)
Otros Autores:	Francine M. Foss (15181313) (author), Basem M. William (15181316) (author), Jonathan E. Brammer (15181319) (author), Sonali M. Smith (15181322) (author), Anca Prica (15181325) (author), Jasmine M. Zain (15181328) (author), Joseph M. Tuscano (15181331) (author), Harsh Shah (15181334) (author), Neha Mehta-Shah (15028830) (author), Praveen Ramakrishnan Geethakumari (15181337) (author), Ben X. Wang (15181340) (author), Stephanie Zantinge (15181343) (author), Lisa Wang (15181346) (author), Ling Zhang (15055348) (author), Anmarie Boutrin (15181349) (author), Weiguang Zhao (15181352) (author), Lily Cheng (15181355) (author), Nathan Standifer (15055246) (author), Lisa Hewitt (15181358) (author), Enowmpey Enowtambong (15181361) (author), Weiping Shao (15181364) (author), Shringi Sharma (15181367) (author), Gianluca Carlesso (15131121) (author), Jeffrey A. Moscow (15056798) (author), Lillian L. Siu (14851075) (author)
Publicado:	2025
Materias:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Hematological Cancers Lymphomas Immunotherapy Antibody immunotherapy
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
por: Julio C. Chavez (15181310)
Publicado: (2025)

Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
por: Julio C. Chavez (15181310)
Publicado: (2025)

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
por: Ibrahim Aldoss (15055961)
Publicado: (2025)

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
por: Ibrahim Aldoss (15055961)
Publicado: (2025)

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
por: Ibrahim Aldoss (15055961)
Publicado: (2025)

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
por: Ibrahim Aldoss (15055961)
Publicado: (2025)

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
por: Ibrahim Aldoss (15055961)
Publicado: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
por: Ulka N. Vaishampayan (15051039)
Publicado: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
por: Ulka N. Vaishampayan (15051039)
Publicado: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
por: Ulka N. Vaishampayan (15051039)
Publicado: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
por: Ulka N. Vaishampayan (15051039)
Publicado: (2025)

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
por: Samuel Rosner (15054884)
Publicado: (2025)

Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
por: Wei Chen (15053713)
Publicado: (2025)

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
por: Wei Chen (15053713)
Publicado: (2025)

Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
por: Wei Chen (15053713)
Publicado: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
por: Fabrice Barlesi (15045504)
Publicado: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
por: Fabrice Barlesi (15045504)
Publicado: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
por: Fabrice Barlesi (15045504)
Publicado: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
por: Fabrice Barlesi (15045504)
Publicado: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
por: Fabrice Barlesi (15045504)
Publicado: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
por: Giuseppe Basile (15051269)
Publicado: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
por: Amir T. Fathi (15313195)
Publicado: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
por: Amir T. Fathi (15313195)
Publicado: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
por: Roger Li (17078665)
Publicado: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Dwight H. Owen (15034782)
Publicado: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Dwight H. Owen (15034782)
Publicado: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Dwight H. Owen (15034782)
Publicado: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Dwight H. Owen (15034782)
Publicado: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Dwight H. Owen (15034782)
Publicado: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
por: Ruiyun Zhang (17142498)
Publicado: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
por: Rohit Thummalapalli (17314483)
Publicado: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lpc1p65rem52k15ffuirpp956h